Edwin Jabbari Mrcp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/882700/publications.pdf

Version: 2024-02-01

20 513 papers citations

23

all docs

23 docs citations 11 h-index

840776

23 times ranked 888059 17 g-index

927 citing authors

#	Article	IF	CITATIONS
1	Genomeâ€Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. Movement Disorders, 2021, 36, 424-433.	3.9	101
2	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	9.0	94
3	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	10.2	62
4	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	8.1	56
5	Variation at the <i>TRIM11</i> locus modifies progressive supranuclear palsy phenotype. Annals of Neurology, 2018, 84, 485-496.	5. 3	37
6	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 768-773.	1.9	29
7	Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 883-888.	1.9	26
8	The genetic and clinicoâ€pathological profile of earlyâ€onset progressive supranuclear palsy. Movement Disorders, 2019, 34, 1307-1314.	3.9	16
9	Automated Brainstem Segmentation Detects Differential Involvement in Atypical Parkinsonian Syndromes. Journal of Movement Disorders, 2020, 13, 39-46.	1.3	16
10	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	7.7	15
11	Tau-targeting antibody therapies: too late, wrong epitope or wrong target?. Nature Medicine, 2021, 27, 1341-1342.	30.7	15
12	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism and Related Disorders, 2020, 79, 121-126.	2.2	11
13	<i>MAPT</i> p.V363I mutation. Neurology: Genetics, 2019, 5, e347.	1.9	10
14	Combining biomarkers for prognostic modelling of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 707-715.	1.9	9
15	Longitudinally extensive transverse myelitis: a rare association with common variable immunodeficiency. Practical Neurology, 2015, 15, 49-52.	1.1	8
16	The clinical dilemma of treating transient ischaemic attack-like symptoms in patients with coexisting arteriovenous malformation. BMJ Case Reports, 2014, 2014, bcr2013201315-bcr2013201315.	0.5	3
17	[P1–258]: THE PROSPECT STUDY: DEVELOPMENT OF A UKâ€BASED LONGITUDINAL OBSERVATIONAL STUDY (PSP, CBD, MSA AND ATYPICAL PARKINSONISM SYNDROMES. Alzheimer's and Dementia, 2017, 13, P348.	OF 0.8	1
18	PO082â€Can csf nfl predict progression in progressive supranuclear palsy?. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A33.1-A33.	1.9	0

#	Article	IF	CITATIONS
19	[O4–02–01]: PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON's AND ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1228.	0.8	O
20	Investigating the contribution of an intronic variation at the trim11 locus to pathological and clinical heterogeneity in progressive supranuclear palsy. Alzheimer's and Dementia, 2020, 16, e042936.	0.8	0